SCHEMBL21419086

SCHEMBL21419086

CC(C)(C)OC(=O)NCCn1ccnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.46
STK17B O94768 1/20 0.44
STK17A Q9UEE5 1/20 0.44
ALDH1A1 P00352 1/20 0.41
GFER P55789 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
DYRK1A Q13627 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24533118 0.92 STK17B (0.51) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL22588365 0.85 KMT2A (0.44) DRD2ALDH1A1GFERTDP1CA12
SCHEMBL3657040 0.84 TLR8 (0.43) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL31522987 0.84 ALDH1A1 (0.41) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL28230449 0.83 ALDH1A1 (0.43) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL29951923 0.82 ALDH1A1 (0.40) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL1568448 0.82 HTT (0.43) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL27750596 0.82 SMN1; SMN2 (0.52) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL21419082 0.81 FLT1 (0.39) DRD2STK17BSTK17AALDH1A1GFER
SCHEMBL31420756 0.80 CA12 (0.52) DRD2ALDH1A1GFERTDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-04-24 US disclosed
CN-112165944-B Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2024-04-09 CN disclosed
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-01-12 US disclosed
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-13 US disclosed
CN-112165944-A Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2021-01-01 CN disclosed
WO-2019191667-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-10-03 WO disclosed
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins EP300, CREBBP, RBBP7 DRD2 4798/4885STK17B 2185/4885STK17A 2005/4885
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 DRD2 4798/4885STK17B 2185/4885STK17A 2005/4885
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 DRD2 4798/4885STK17B 2185/4885STK17A 2005/4885
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 DRD2 4798/4885STK17B 2185/4885STK17A 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.